Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial

T. Susanna Meijer*, Mark C. Burgmans, Marta Fiocco, Lioe Fee de Geus-Oei, Ellen Kapiteijn, Eleonora M. de Leede, Christian H. Martini, Rutger W. van der Meer, Fred G.J. Tijl, Alexander L. Vahrmeijer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)
4 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences